Pittsburgh, Pa. , Aug. 13, 2024 /CNW/ - MolecuLight Corp.
, the global leader in fluorescence imaging technology for real-time detection of harmful bacteria in wound care, is proudly reaffirmed in their commitment to equitable wound care with a recent publication by lead author Dr. Charles Andersen and colleagues, "Bacterial Fluorescence Imaging to Address Racial Inequities in Wound Infection Assessment," published in the Advances in Skin & Wound Care journal. The article highlights the systemic inequities in healthcare that fuel preventable suffering and premature death among racial and ethnic minority populations.
A prime example is the stark disparity in diabetes outcomes: nationwide surveys led by the Centers for Disease Control and Prevention (CDC) revealed that in 2019, Black Americans were twice as likely to die from diabetes complications than White Americans i . This alarming statistic is a grim reminder of the higher rates of diabetes, obesity, and other chronic health conditions plaguing these communities, driven by a complex web of factors including limited access and suboptimal quality of healthcare. Disproportionally poor health outcomes are near-universal for Black Americans, including wounds.
Between 2013-2014, Black Americans with diabetic ulcers in rural areas faced double the risk of major leg amputation or death following hospitalization compared to their White counterparts residing in similar regions ii . "There are now technologies that can identify more.